Nexalin Technology (NASDAQ:NXL – Get Free Report) and AxoGen (NASDAQ:AXGN – Get Free Report) are both small-cap business services companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, earnings, profitability, risk and institutional ownership.
Earnings and Valuation
This table compares Nexalin Technology and AxoGen”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nexalin Technology | $162,078.00 | 334.89 | -$4.65 million | ($0.64) | -6.59 |
| AxoGen | $159.01 million | 3.50 | -$21.72 million | ($0.32) | -39.50 |
Nexalin Technology has higher earnings, but lower revenue than AxoGen. AxoGen is trading at a lower price-to-earnings ratio than Nexalin Technology, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Analyst Recommendations
This is a breakdown of current ratings and recommmendations for Nexalin Technology and AxoGen, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nexalin Technology | 0 | 0 | 1 | 0 | 3.00 |
| AxoGen | 0 | 0 | 4 | 0 | 3.00 |
Nexalin Technology currently has a consensus target price of $3.00, indicating a potential downside of 28.91%. AxoGen has a consensus target price of $15.00, indicating a potential upside of 18.67%. Given AxoGen’s higher probable upside, analysts plainly believe AxoGen is more favorable than Nexalin Technology.
Profitability
This table compares Nexalin Technology and AxoGen’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nexalin Technology | -3,407.98% | -187.59% | -167.21% |
| AxoGen | -7.91% | -14.91% | -7.49% |
Insider and Institutional Ownership
0.6% of Nexalin Technology shares are held by institutional investors. Comparatively, 80.3% of AxoGen shares are held by institutional investors. 24.0% of Nexalin Technology shares are held by insiders. Comparatively, 7.0% of AxoGen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
AxoGen beats Nexalin Technology on 8 of the 13 factors compared between the two stocks.
About Nexalin Technology
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.
About AxoGen
AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.
Receive News & Ratings for Nexalin Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexalin Technology and related companies with MarketBeat.com's FREE daily email newsletter.
